INSM
Price:
$72.05
Market Cap:
$12.89B
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated ...[Read more]
Industry
Biotechnology
IPO Date
2000-06-01
Stock Exchange
NASDAQ
Ticker
INSM
According to Insmed Incorporated’s latest financial reports and current stock price. The company's current ROE is 1.26%. This represents a change of -789.94% compared to the average of -182.54% of the last 4 quarters.
The mean historical ROE of Insmed Incorporated over the last ten years is -103.49%. The current 1.26% ROE has changed -1316.91% with respect to the historical average. Over the past ten years (40 quarters), INSM's ROE was at its highest in in the September 2022 quarter at 437.75%. The ROE was at its lowest in in the June 2024 quarter at -774.41%.
Average
-103.49%
Median
-101.54%
Minimum
-547.50%
Maximum
225.83%
Discovering the peaks and valleys of Insmed Incorporated ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 417.04%
Maximum Annual ROE = 225.83%
Minimum Annual Increase = -141.25%
Minimum Annual ROE = -547.50%
Year | ROE | Change |
---|---|---|
2023 | 225.83% | -141.25% |
2022 | -547.50% | 417.04% |
2021 | -105.89% | -0.66% |
2020 | -106.60% | 9.67% |
2019 | -97.20% | -37.58% |
2018 | -155.70% | 191.82% |
2017 | -53.36% | -53.24% |
2016 | -114.11% | 200.94% |
2015 | -37.92% | -10.80% |
2014 | -42.50% | 8.64% |
The current ROE of Insmed Incorporated (INSM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-142.52%
5-year avg
-126.27%
10-year avg
-103.49%
Insmed Incorporated’s ROE is less than Ascendis Pharma A/S (212.63%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than BeiGene, Ltd. (-25.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Blueprint Medicines Corporation (-47.66%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Avidity Biosciences, Inc. (-27.66%), greater than Revolution Medicines, Inc. (-33.67%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than SpringWorks Therapeutics, Inc. (-48.21%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Janux Therapeutics, Inc. (-10.46%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Edgewise Therapeutics, Inc. (-26.83%), less than Harmony Biosciences Holdings, Inc. (23.16%), less than Halozyme Therapeutics, Inc. (156.40%), less than Agios Pharmaceuticals, Inc. (70.20%), greater than Ultragenyx Pharmaceutical Inc. (-187.12%),
Company | ROE | Market cap |
---|---|---|
212.63% | $7.81B | |
-103.92% | $4.07B | |
-25.12% | $21.09B | |
-32.52% | $2.03B | |
-47.66% | $5.88B | |
-98.94% | $8.19B | |
-27.66% | $4.03B | |
-33.67% | $8.19B | |
-22.40% | $1.29B | |
-48.21% | $2.88B | |
-41.74% | $746.55M | |
-10.46% | $3.55B | |
31.99% | $167.58M | |
-26.83% | $2.67B | |
23.16% | $1.82B | |
156.40% | $6.09B | |
70.20% | $2.18B | |
-187.12% | $4.33B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insmed Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Insmed Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Insmed Incorporated's ROE?
How is the ROE calculated for Insmed Incorporated (INSM)?
What is the highest ROE for Insmed Incorporated (INSM)?
What is the 3-year average ROE for Insmed Incorporated (INSM)?
What is the 5-year average ROE for Insmed Incorporated (INSM)?
How does the current ROE for Insmed Incorporated (INSM) compare to its historical average?